NCT02948751View on ClinicalTrials.gov

Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer

CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

December 18, 2019

Study Completion Date

December 18, 2019

Conditions
Breast CancerLeptomeningeal Metastasis
Interventions
DEVICE

OncoCEE

The CSF sample will be to delivered to Biocept's laboratory for processing, and it will be evaluated for CTCs using OncoCEETM microchannel technology. This CSF sample will also be tested for cell-free circulating tumor DNA (ctDNA).

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

Sponsors

Collaborators (1)

Biocept, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Biocept, Inc.

INDUSTRY

lead

Columbia University

OTHER

NCT02948751 - Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer | Biotech Hunter | Biotech Hunter